{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:40:40Z","timestamp":1783068040107,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To describe the morphology and histopathology of the vitreoretinal interface (VRI) in eyes with pseudoexfoliation syndrome (PEX) and epiretinal membrane (ERM) (pERM) in comparison to eyes without PEX and idiopathic ERM (iERM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>\u00a0Specimens of ERM and internal limiting membrane (ILM) were obtained during pars plana vitrectomy with membrane peeling from 10 symptomatic eyes with pERM and 16\u00a0eyes with iERM. Specimens were processed as flat-mounts for immunocytochemistry and prepared by ultrathin series sectioning for transmission electron microscopy (TEM). Cellular and extracellular composition were compared and correlated with clinical data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The extracellular distribution of the VRI showed significant differences between pERM and iERM in the following aspects. Immunostaining revealed that all pERM specimens were positive for fibrillin-1, collagen IV and TGF\u03b21, which are key regulatory factors or structural components of the extracellular matrix, while these markers were rarely detected positive in the iERM group. Glial cell markers, GFAP and vimentin, were consistently positive in both groups. TEM revealed abundant vitreous collagen and evidence of vitreous remodeling in pERM eyes, including the presence of fibrous long-spacing collagen (FLSC). In contrast, iERM specimens showed sparse collagen strands with no evidence of FLSC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Eyes with pERM showed excessive production and subsequent accumulation of extracellular matrix material and elastic proteins such as fibrilin compared to eyes with iERM. Our data suggest that PEX may affect the VRI in a manner similar to the anterior segment, based on the detection and alteration of common structures such as collagen in the pERM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00417-025-06854-1","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:16:50Z","timestamp":1747790210000},"page":"2227-2236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vitreoretinal interface features in epiretinal membrane associated with pseudoexfoliation syndrome"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-6675","authenticated-orcid":false,"given":"Denise","family":"Vogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Deiters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Zaytseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda G.","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian E.","family":"Klaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"5","key":"6854_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ajo.2006.01.047","volume":"141","author":"U Schl\u00f6tzer-Schrehardt","year":"2006","unstructured":"Schl\u00f6tzer-Schrehardt U, Naumann GO (2006) Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 141(5):921\u2013937. https:\/\/doi.org\/10.1016\/j.ajo.2006.01.047","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"6854_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1479-7364-6-22","volume":"6","author":"E Elhawy","year":"2012","unstructured":"Elhawy E, Kamthan G, Dong CQ, Danias J (2012) Pseudoexfoliation syndrome, a systemic disorder with ocular manifestations. Hum Genomics 6(1):22. https:\/\/doi.org\/10.1186\/1479-7364-6-22","journal-title":"Hum Genomics"},{"issue":"1","key":"6854_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/01.ijg.0000243470.13343.8b","volume":"16","author":"SM Jeng","year":"2007","unstructured":"Jeng SM, Karger RA, Hodge DO, Burke JP, Johnson DH, Good MS (2007) The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma 16(1):117\u2013121. https:\/\/doi.org\/10.1097\/01.ijg.0000243470.13343.8b","journal-title":"J Glaucoma"},{"issue":"6","key":"6854_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jcrs.2014.09.039","volume":"41","author":"A Govetto","year":"2015","unstructured":"Govetto A, Lorente R, V\u00e1zquez de Parga P, Rojas L, Moreno C, Lagoa F, Lorente B (2015) Frequency of pseudoexfoliation among patients scheduled for cataract surgery. J Cataract Refract Surg 41(6):1224\u20131231. https:\/\/doi.org\/10.1016\/j.jcrs.2014.09.039","journal-title":"J Cataract Refract Surg"},{"issue":"9","key":"6854_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/ijg.0000000000001851","volume":"30","author":"JY Lee","year":"2021","unstructured":"Lee JY, Sung KR, Kim YJ (2021) Comparison of the prevalence and clinical characteristics of epiretinal membrane in pseudoexfoliation and primary open-angle glaucoma. J Glaucoma 30(9):859\u2013865. https:\/\/doi.org\/10.1097\/ijg.0000000000001851","journal-title":"J Glaucoma"},{"issue":"2","key":"6854_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00417-021-05373-z","volume":"260","author":"SK Ad\u0131yeke","year":"2022","unstructured":"Ad\u0131yeke SK, Kutlu N, \u00d6zen K, Doran MA, Demirba\u015f K, Ture G, Talay E (2022) Is pseudoexfoliation syndrome associated with vitreoretinal interface abnormalities? Graefes Arch Clin Exp Ophthalmol 260(2):431\u2013437. https:\/\/doi.org\/10.1007\/s00417-021-05373-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"6854_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/iub.2606","volume":"74","author":"S Mastronikolis","year":"2022","unstructured":"Mastronikolis S, Pagkalou M, Baroutas G, Kyriakopoulou K, Makri \u039fE, Georgakopoulos CD (2022) Pseudoexfoliation syndrome: The critical role of the extracellular matrix in pathogenesis and treatment. IUBMB Life 74(10):995\u20131002. https:\/\/doi.org\/10.1002\/iub.2606","journal-title":"IUBMB Life"},{"issue":"16","key":"6854_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/cells11162531","volume":"11","author":"L Bianchi","year":"2022","unstructured":"Bianchi L, Altera A, Barone V, Bonente D, Bacci T, De Benedetto E, Bini L, Tosi GM, Galvagni F, Bertelli E (2022) Untangling the extracellular matrix of idiopathic epiretinal membrane: a path winding among structure, interactomics and translational medicine. Cells 11(16):2531. https:\/\/doi.org\/10.3390\/cells11162531","journal-title":"Cells"},{"key":"6854_CR9","doi-asserted-by":"publisher","unstructured":"Govetto A, Lalane RA 3rd, Sarraf D, Figueroa MS, Hubschman JP (2017) Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme. Am J Ophthalmol 175:99-113.\u00a0https:\/\/doi.org\/10.1016\/j.ajo.2016.12.006","DOI":"10.1016\/j.ajo.2016.12.006"},{"issue":"3","key":"6854_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2298\/VSP1203231D","volume":"69","author":"J Djordjevi\u0107-Joci\u0107","year":"2012","unstructured":"Djordjevi\u0107-Joci\u0107 J, Zlatanovi\u0107 G, Veselinovi\u0107 D, Jovanovi\u0107 P, Djordjevi\u0107 V, Zvezdanovi\u0107 L, Stankovi\u0107-Babi\u0107 G, Vujanovi\u0107 M, Ceki\u0107 S, Zenkel M, Schlotzer-Schrehardt U (2012) Transforming growth factor beta1, matrix-metalloproteinase-2 and its tissue inhibitor in patients with pseudoexfoliation glaucoma\/syndrome. Vojnosanit Pregl 69(3):231\u2013236","journal-title":"Vojnosanit Pregl"},{"key":"6854_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.exer.2017.08.017","volume":"165","author":"MS Filla","year":"2017","unstructured":"Filla MS, Dimeo KD, Tong T, Peters DM (2017) Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells. Exp Eye Res 165:7\u201319. https:\/\/doi.org\/10.1016\/j.exer.2017.08.017","journal-title":"Exp Eye Res"},{"issue":"6","key":"6854_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1006\/exer.2001.1084","volume":"73","author":"U Schl\u00f6tzer-Schrehardt","year":"2001","unstructured":"Schl\u00f6tzer-Schrehardt U, Zenkel M, K\u00fcchle M, Sakai LY, Naumann GO (2001) Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res 73(6):765\u2013780. https:\/\/doi.org\/10.1006\/exer.2001.1084","journal-title":"Exp Eye Res"},{"issue":"8","key":"6854_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/1357-2725(95)00028-n","volume":"27","author":"CM Kielty","year":"1995","unstructured":"Kielty CM, Shuttleworth CA (1995) Fibrillin-containing microfibrils: structure and function in health and disease. Int J Biochem Cell Biol 27(8):747\u2013760. https:\/\/doi.org\/10.1016\/1357-2725(95)00028-n","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"6854_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3892\/ijmm.2017.3343","volume":"41","author":"S Schrenk","year":"2018","unstructured":"Schrenk S, Cenzi C, Bertalot T, Conconi MT, Di Liddo R (2018) Structural and functional failure of fibrillin-1 in human diseases (Review). Int J Mol Med 41(3):1213\u20131223. https:\/\/doi.org\/10.3892\/ijmm.2017.3343","journal-title":"Int J Mol Med"},{"issue":"Suppl 1","key":"6854_CR15","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/ijg.0000000000000902","volume":"27","author":"M Zenkel","year":"2018","unstructured":"Zenkel M (2018) Extracellular matrix regulation and dysregulation in exfoliation syndrome. J Glaucoma 27(Suppl 1):S24-s28. https:\/\/doi.org\/10.1097\/ijg.0000000000000902","journal-title":"J Glaucoma"},{"issue":"3","key":"6854_CR16","doi-asserted-by":"publisher","first-page":"e56450","DOI":"10.7759\/cureus.56450","volume":"16","author":"D Upasani","year":"2024","unstructured":"Upasani D, Daigavane S (2024) Pseudoexfoliation syndrome presenting with bilateral visual impairment and intraocular pressure discrepancy: a case report. Cureus 16(3):e56450. https:\/\/doi.org\/10.7759\/cureus.56450","journal-title":"Cureus"},{"key":"6854_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06667-8","author":"LV Tien","year":"2024","unstructured":"Tien LV, Yamamoto M, Tagami M, Misawa N, Honda S (2024) Immunohistochemical expression of Fibrillin-1 in idiopathic epiretinal membranes. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-024-06667-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"6854_CR18","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/art.10621","volume":"46","author":"EY Kissin","year":"2002","unstructured":"Kissin EY, Lemaire R, Korn JH, Lafyatis R (2002) Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation. Arthritis Rheum 46(11):3000\u20133009. https:\/\/doi.org\/10.1002\/art.10621","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6854_CR19","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-021-05156-6","volume":"259","author":"A Altera","year":"2021","unstructured":"Altera A, Tosi GM, Regoli M, De Benedetto E, Bertelli E (2021) The extracellular matrix complexity of idiopathic epiretinal membranes and the bilaminar arrangement of the associated internal limiting membrane in the posterior retina. Graefes Arch Clin Exp Ophthalmol 259(9):2559\u20132571. https:\/\/doi.org\/10.1007\/s00417-021-05156-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"6854_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.exer.2005.12.007","volume":"83","author":"MA Gamulescu","year":"2006","unstructured":"Gamulescu MA, Chen Y, He S, Spee C, Jin M, Ryan SJ, Hinton DR (2006) Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res 83(1):212\u2013222. https:\/\/doi.org\/10.1016\/j.exer.2005.12.007","journal-title":"Exp Eye Res"},{"key":"6854_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.matbio.2022.04.002","volume":"109","author":"SE Wilson","year":"2022","unstructured":"Wilson SE, Shiju TM, Sampaio LP, Hilgert GSL (2022) Corneal fibroblast collagen type IV negative feedback modulation of TGF beta: A fibrosis modulating system likely active in other organs. Matrix Biol 109:162\u2013172. https:\/\/doi.org\/10.1016\/j.matbio.2022.04.002","journal-title":"Matrix Biol"},{"issue":"3","key":"6854_CR22","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1167\/iovs.02-0365","volume":"44","author":"U Schl\u00f6tzer-Schrehardt","year":"2003","unstructured":"Schl\u00f6tzer-Schrehardt U, Lommatzsch J, K\u00fcchle M, Konstas AG, Naumann GO (2003) Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome\/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 44(3):1117\u20131125. https:\/\/doi.org\/10.1167\/iovs.02-0365","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"6854_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/biomimetics7030087","volume":"7","author":"RB Diller","year":"2022","unstructured":"Diller RB, Tabor AJ (2022) The role of the Extracellular Matrix (ECM) in wound healing: a review. Biomimetics (Basel) 7(3):87. https:\/\/doi.org\/10.3390\/biomimetics7030087","journal-title":"Biomimetics (Basel)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06854-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:45:21Z","timestamp":1757137521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06854-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6854"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06854-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board and the Ethics Committee of the Ludwig-Maximilians-University, Munich, approved the surgical removal as well as the histopathologic preparation and analysis of the patients\u2019 specimens (No. 22\u20131034). The study was conducted according to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Denise Vogt: travel reimbursements and speaker fees by AbbVie Germany GmbH & Co. KG, Novartis Pharma GmbH and Bayer Vital GmbH.Viktoria Deiters: travel reimbursement by AbbVie, speaker fee by Novartis.Yulia Zaytseva: None to declare.Ricarda G. Schumann: research grant, travel reimbursement, personal fee and non-financial support by Novartis, Bayer, AbbVie, Roche and Zeiss.Armin Wolf: Consultant with AbbVie, Bayer, Boehringer Ingelheim, Novartis, Pixium, Roche, Sandoz, and Zeiss.Siegfried G. Priglinger: Novartis Pharma GmbH advisory board\/honoraria, Pharm Allergan advisory board\/honoraria, Zeiss advisory board\/honoraria, BVIadvisory board\/honoraria.Julian E. Klaas: Consultant for ROCHE. Speaker Honoraria for Roche, Novartis.All authors attest that they meet the current ICMJE criteria for authorship.The authors have no proprietary interest in any aspect of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study uses surgically removed human tissue from human participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}